The Role of GSK3β in T Lymphocytes in the Tumor Microenvironment

Immunotherapy options for patients with cancer have emerged following decades of research on immune responses against tumors. Most treatments in this category harness T cells with specificity for tumor associated antigens, neoantigens, and cancer-testis antigens. GSK3 beta is a serine-threonine kinase with the highest number of substrates and multifaceted roles in cell function including immune cells. Importantly, inhibitors of GSK3 beta are available for clinical and research use. Here, we review the possible role of GSK3 beta in the immune tumor microenvironment, with goal to guide future research that tests GSK3 beta inhibition as an immunotherapy adjunct.